PET-CT scan

What it is

A PET-CT scan is a combined imaging test that joins PET and CT in one session to show both body function and anatomy. In cancer care, the most important point is that PET-CT can often stage disease, assess treatment response, and look for recurrence more accurately than either PET or CT alone in selected situations.

PET stands for positron emission tomography. It uses a small amount of radioactive tracer, most often 18F-FDG, a glucose-like substance, to show how active tissues are metabolically. CT stands for computed tomography. It uses x-rays to show detailed body structure. When the two are fused, doctors can see both where an abnormality is and how active it is.

PET-CT is widely used in oncology, but it is not a general screening test for healthy people. It is ordered for a specific clinical question, such as initial staging, checking whether treatment is working, planning radiotherapy, or evaluating suspected relapse. In India, PET-CT is available in many tertiary cancer centres and large private hospitals, but access and cost can vary by city and state.

Part of the test	What it shows	Common role
PET	Metabolic or functional activity	Detects areas taking up tracer more than expected
CT	Anatomy and structure	Shows size, shape, and exact location
PET-CT together	Function plus structure	Improves localisation and interpretation

How it works

Before the scan, a tracer is injected into a vein. The most common tracer in cancer imaging is FDG. Cells that use more glucose often take up more FDG. Many cancers do this, which is why they can appear as "hot spots" on PET images. After injection, there is usually a waiting period so the tracer can circulate and be taken up by tissues.

The CT part is then performed, and the PET scanner detects signals from the tracer. Software combines the two image sets into one study. This helps distinguish, for example, whether increased tracer uptake is in a lymph node, bowel loop, scar tissue, or normal organ.

Different tracers are used for different clinical questions. Examples include:

1. FDG PET-CT: most common in many cancers such as lymphoma and many lung cancers.
2. Ga-68 DOTATATE PET-CT: often used for neuroendocrine tumours.
3. PSMA PET-CT: used in prostate cancer in selected settings.
4. Other tracers: used for specific brain, heart, or tumour indications.

Preparation matters because it affects image quality. Patients are often asked to avoid strenuous exercise before the test and to fast for several hours, especially for FDG PET-CT. Blood glucose is commonly checked because high glucose can reduce FDG image quality. Diabetic patients may need special scheduling instructions.

Evidence and uses

PET-CT has become an important tool in cancer imaging because it combines functional and structural information. Reviews in nuclear medicine and oncology literature describe PET-CT as particularly useful where management depends on accurate staging or early response assessment.

Common cancer-related uses include:

• Initial staging: to see how far a known cancer has spread
• Restaging: to reassess disease after treatment or if the situation changes
• Response assessment: to see whether chemotherapy, targeted therapy, immunotherapy, or radiation is working
• Detection of recurrence: to investigate suspected return of cancer
• Radiotherapy planning: to help define active tumour areas
• Biopsy guidance: to help identify the most active or informative site in some cases

PET-CT is especially established in several cancers, including many lymphomas, non-small cell lung cancer, colorectal cancer recurrence work-up, head and neck cancers, and selected gynecologic and oesophageal cancers. It is also useful in some non-cancer conditions, such as infection, inflammation, and certain cardiac or neurologic indications, but cancer is the most common reason many patients encounter it.

That said, PET-CT is not equally useful for every cancer. Some tumours are not very FDG-avid, and very small lesions may be missed. Inflammation, infection, recent surgery, and healing tissue can also show increased uptake and create false-positive results. A PET-CT result therefore needs to be interpreted along with symptoms, examination, pathology, blood tests, and other imaging.

A normal PET-CT does not always rule out cancer, and an abnormal PET-CT does not by itself prove cancer. Tissue diagnosis with biopsy is still needed when the result would change treatment and the diagnosis is uncertain.

Diagnosis / how it's measured

PET-CT is a diagnostic imaging procedure, not a blood test. The report usually describes:

• the tracer used
• the body area scanned
• sites of abnormal uptake
• CT findings such as masses or enlarged lymph nodes
• a combined impression of what the findings may mean

One term patients often see is SUV, or standardised uptake value. SUV is a semi-quantitative measure of tracer uptake in a region. Higher SUV can suggest greater metabolic activity, but it is not a diagnosis by itself. SUV can be affected by blood glucose, timing after injection, body composition, scanner protocol, and the specific tumour type.

Some PET-CT scans use oral or intravenous contrast for the CT portion, while others use a low-dose CT mainly for localisation and attenuation correction. If contrast is planned, kidney function and prior contrast allergy history may matter.

During the test, the patient lies still on a table that moves through the scanner. The scan itself is painless, though the injection, fasting, waiting period, and need to remain still can be uncomfortable for some people. Claustrophobia is usually milder than with MRI because PET-CT scanners are more open, but it can still be an issue.

When to see a clinician

You should discuss a PET-CT with your clinician if you have been advised to get one for cancer staging, treatment response, or suspected recurrence and you are unsure why it is needed. Ask what specific question the scan is meant to answer, because that helps you understand its value and limits.

Tell the imaging team before the scan if you are pregnant, could be pregnant, breastfeeding, diabetic, have trouble lying flat, have severe claustrophobia, or have had a reaction to CT contrast before. Also mention recent infection, surgery, vaccination, chemotherapy, radiation, or use of growth-factor injections, because these can affect interpretation.

After the scan, contact your clinician if you develop symptoms after contrast, such as rash or breathing difficulty, though serious reactions are uncommon. Most patients can resume normal activities soon after the test, but they should follow the centre's instructions about hydration and contact with infants or pregnant people for the rest of the day if advised.

Limitations and open questions

PET-CT is powerful, but it has limits. It exposes the patient to ionising radiation from both the PET tracer and the CT scan, so it should be used when the expected clinical benefit is clear. The exact dose varies by protocol, body size, tracer, and whether a diagnostic CT with contrast is included.

Accuracy also depends on the cancer type, lesion size, timing of the scan, and the tracer used. FDG PET-CT is excellent for some cancers but less informative for others. Newer tracer-based PET-CT approaches, such as PSMA and DOTATATE imaging, have improved performance in selected diseases, but they are not interchangeable with FDG.

Evidence supports PET-CT in many oncology settings, but not every use improves outcomes or is cost-effective. In some situations, it changes management substantially; in others, it may add little beyond standard imaging. Access, affordability, and tracer availability remain practical issues in India and elsewhere.

Interpretation can also be challenging in the era of immunotherapy, where treatment can cause inflammatory changes that mimic progression. Evidence continues to evolve on the best timing and criteria for response assessment in different cancers. For patients and families, the key point is that PET-CT is best understood as one part of decision-making, not a stand-alone answer.